Astrazeneca Share News (AZN)

AstraZeneca steps up push into cancer immunotherapy

By Ben Hirschler LONDON, July 31 (Reuters) - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumour types. The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing

London midday: Earnings come in mixed as investors watch US data, Fed

- Shell, BG Group and Intu lead the risers - Weir, Schroders and Lloyds fall - Afren drops after suspending directors - US data and Fed keep investors cautious techMARK 2,763.54 -0.57% FTSE 100 6,763.04 -0.15% FTSE 250 15,495.73 -0.86% London stocks were trading in the red for a second straight da

UPDATE 3-AstraZeneca raises forecasts after seeing off Pfizer

* One-off payments and tax benefit flatter Q2 results * Investors focused on possible Pfizer return * Q2 revenue $6.45 billion vs consensus $6.29 billion * Q2 core EPS $1.30 vs consensus $1.10 * Now assuming generic Nexium in U.S. from Oct. 1 (Adds CEO comments from conf

TOP NEWS: Strong Results From Shell Highlight UK Corporate Earnings

UPDATE: AstraZeneca Raises Guidance Despite Interim Profit Fall

Astrazeneca raises guidance after better-than-expected Q2

- Core EPS and revenue outlook raised - H1 revenue up 3%, Q2 revenue up 4% - Q2 PBT of $1.89bn Astrazeneca has lifted its guidance for the year after delivering a 4% increase in second quarter revenue to $6.4bn, ahead of expectations. Half year turnover at the drugs giant climbed 3%, driven by ga

UPDATE 2-AstraZeneca raises forecasts after seeing off Pfizer

* One-off payments and tax benefit flatter Q2 results * Investors focused on possible Pfizer return * Q2 revenue $6.45 billion vs consensus $6.29 billion * Q2 core EPS $1.30 vs consensus $1.10 * Now assuming generic Nexium in U.S. from Oct. 1 (Adds analyst comment, share

AstraZeneca Raises Revenue And Earnings Guidance Despite Profit Fall

UPDATE 1-AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

* Q2 revenue $6.45 billion vs consensus $6.29 billion * Q2 core EPS $1.30 vs consensus $1.10 * Drugmaker raises full-year guidance * Now assuming generic Nexium in U.S. from Oct. 1 (Adds detail on products, background) By Ben Hirschler LONDON, July 31 (Reuters) - A

MARKET COMMENT: UK Stocks To Open Higher With Earnings In Focus

AstraZeneca smashes forecasts in Q2 after seeing off Pfizer

LONDON, July 31 (Reuters) - AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago. Sales in the first quarter rose 4 percent to $6.45 billion, des

UK Earnings, Trading Statements Calendar - Week Ahead

MARKET COMMENT: UK Stocks Fall As US GDP Surge Turns Attention To Fed

UK Earnings, Trading Statements Calendar - Week Ahead

Sanofi, Regeneron drug cuts cholesterol in nine late-stage trials

* Sanofi to file drug for US and EU approval by year-end * Nine Phase III ODYSSEY trials meet primary endpoint * Alirocumab "generally well tolerated" in trials By Natalie Huet PARIS, July 30 (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partne